Additionally, TGFB2 methylation correlates inversely with numerous T cell receptor (TCR) signaling components—HLA-D molecules, CD3D, CD28, and LCK—all of which are upregulated in the tumor when TGFB2 is weakly methylated [39]. The gene discussed is CD3D; the disease is neoplasm.